Related Experiment Video
Updated: Oct 4, 2025

Visualizing Lung Cellular Adaptations during Combined Ozone and LPS Induced Murine Acute Lung Injury
Published on: March 21, 2021
Implication of mitochondrial ROS-NLRP3 inflammasome axis during two-hit mediated acute lung injury in mice
Gayatri Puri1, Amarjit S Naura1
1Department of Biochemistry, Panjab University, Chandigarh, India.
Abstract:
Acute lung injury (ALI) caused by acid aspiration often accompanies bacterial components leading to exaggerated inflammation and can result in acute respiratory distress syndrome (ARDS), but the underlying mechanisms behind such an exacerbation remain unclear. NLRP3 inflammasome and mitochondrial ROS (mtROS) have been implicated in ALI but its role in injury caused through two hit i.e. Hydrochloric acid (HCl) + Lipopolysaccharide (LPS) is not known. Therefore, the present study is designed to elucidate the role of mtROS-NLPR3 inflammasome upon "two-hit" mediated ALI. Our data showed that "two-hit" induced ALI results in aggravated lung inflammation as compared to either of single hit(s) as reflected by a steep increase in inflammatory cells particularly neutrophils in bronchoalveolar lavage fluid (BALF). Further, enhanced inflammation was associated with increased mtROS as depicted by data on mean fluorescence intensity (MFI) of MitoSOX+ neutrophils and macrophages in BALF of two-hit simulated mice. Importantly, ALI results in activation of NLRP3 inflammasome as reflected by active caspase-1 protein expression and IL-1β levels. Interestingly, NLRP3 inflammasome inhibitor, MCC950 suppressed the lung inflammation remarkably. Further, Mito-tempo, a mitochondrial-targeted antioxidant, halted "two-hit" mediated NLRP3 inflammasome activation and IL-1β release followed by amelioration of lung inflammation. Suppression in MFI of MitoSOX+ stained neutrophils and macrophages by Mito-tempo was associated with down-regulation of phospho-p65-NF-κB and its dependent genes (IL-1β/TNF-α/IL-6). Overall, our data suggest that NLRP3 inflammasome activation by mtROS plays a critical role in pathogenesis of exaggerated inflammation and therefore targeting mtROS-NLRP3 inflammasome axis may be an attractive option for combating ALI/ARDS.
Insights
Acid aspiration combined with bacterial components exacerbates acute lung injury (ALI). Targeting mitochondrial ROS and NLRP3 inflammasome activation may combat ALI and ARDS.
Area of Science:
- Pulmonary Medicine
- Immunology
- Cellular Biology
Background:
- Acid aspiration can cause acute lung injury (ALI), often worsened by bacterial components, leading to acute respiratory distress syndrome (ARDS).
- The mechanisms behind this inflammation exacerbation, particularly involving the NLRP3 inflammasome and mitochondrial reactive oxygen species (mtROS), in a
- two-hit
- ALI model are not well understood.
Purpose of the Study:
- To investigate the role of the mitochondrial ROS (mtROS)-NLRP3 inflammasome axis in
- two-hit
- (Hydrochloric acid + Lipopolysaccharide) induced ALI.
Main Methods:
- Induction of
- two-hit
- ALI in mice.
- Assessment of inflammatory cell infiltration in bronchoalveolar lavage fluid (BALF).
- Measurement of mtROS using MitoSOX staining.
- Evaluation of NLRP3 inflammasome activation (caspase-1, IL-1β).
- Pharmacological inhibition of NLRP3 inflammasome (MCC950) and mtROS (Mito-tempo).
- Analysis of NF-κB signaling pathway activation.
Main Results:
- The
- two-hit
- model significantly aggravated lung inflammation compared to single insults.
- Increased mtROS levels were observed in BALF neutrophils and macrophages.
- Activated NLRP3 inflammasome, evidenced by increased active caspase-1 and IL-1β.
- NLRP3 inhibition (MCC950) and mtROS scavenging (Mito-tempo) ameliorated lung inflammation.
- Mito-tempo treatment reduced mtROS, NLRP3 activation, and downstream inflammatory gene expression (IL-1β, TNF-α, IL-6) via NF-κB inhibition.
Conclusions:
- mtROS-mediated NLRP3 inflammasome activation is a critical driver of exaggerated inflammation in
- two-hit
- ALI.
- Targeting the mtROS-NLRP3 inflammasome axis presents a promising therapeutic strategy for ALI and ARDS.

